15/07/2025
A new injection treats 15 cancers in minutes.
And England is now offering the injection.
In a major advancement for cancer care, England has become the first country in Europe to offer an injectable version of the immunotherapy drug nivolumab (Opdivo), dramatically reducing treatment time for thousands of patients.
Traditionally delivered via a one-hour IV drip, the new injection takes just three to five minutes to administer and is approved for use in treating up to 15 types of cancer, including lung, bowel, and skin cancers. The shift is expected to benefit 15,000 patients annually while saving hospitals more than a full year’s worth of treatment time in total.
Approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the injectable form retains the same cancer-fighting power by helping the immune system target malignant cells. The change marks a major step in the NHS’s push to modernize cancer care, making life-saving treatment faster and more accessible. Experts view this as a promising sign of a “golden age” in cancer innovation, calling for sustained public investment and policy support to keep pace with emerging breakthroughs.
Boseley, S. (2025, April 30). Cancer patients in England to be first in Europe to be offered immunotherapy jab. The Guardian.